Eli Lilly and Co (LLY)
749.05
-0.87
(-0.12%)
USD |
NYSE |
Nov 22, 11:35
Eli Lilly Research and Development Expense (Quarterly): 2.734B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.734B |
| June 30, 2024 | 2.711B |
| March 31, 2024 | 2.523B |
| December 31, 2023 | 2.563B |
| September 30, 2023 | 2.409B |
| June 30, 2023 | 2.356B |
| March 31, 2023 | 1.985B |
| December 31, 2022 | 1.996B |
| September 30, 2022 | 1.803B |
| June 30, 2022 | 1.782B |
| March 31, 2022 | 1.610B |
| December 31, 2021 | 1.898B |
| September 30, 2021 | 1.705B |
| June 30, 2021 | 1.655B |
| March 31, 2021 | 1.672B |
| December 31, 2020 | 1.838B |
| September 30, 2020 | 1.465B |
| June 30, 2020 | 1.390B |
| March 31, 2020 | 1.392B |
| December 31, 2019 | 1.581B |
| September 30, 2019 | 1.381B |
| June 30, 2019 | 1.402B |
| March 31, 2019 | 1.230B |
| December 31, 2018 | 1.392B |
| September 30, 2018 | 1.281B |
| Date | Value |
|---|---|
| June 30, 2018 | 1.271B |
| March 31, 2018 | 1.108B |
| December 31, 2017 | 1.226B |
| September 30, 2017 | 1.34B |
| June 30, 2017 | 1.272B |
| March 31, 2017 | 1.258B |
| December 31, 2016 | 1.517B |
| September 30, 2016 | 1.236B |
| June 30, 2016 | 1.336B |
| March 31, 2016 | 1.221B |
| December 31, 2015 | 1.444B |
| September 30, 2015 | 1.143B |
| June 30, 2015 | 1.170B |
| March 31, 2015 | 1.039B |
| December 31, 2014 | 1.186B |
| September 30, 2014 | 1.243B |
| June 30, 2014 | 1.195B |
| March 31, 2014 | 1.109B |
| December 31, 2013 | 1.475B |
| September 30, 2013 | 1.377B |
| June 30, 2013 | 1.330B |
| March 31, 2013 | 1.348B |
| December 31, 2012 | 1.463B |
| September 30, 2012 | 1.343B |
| June 30, 2012 | 1.321B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.390B
Minimum
Jun 2020
2.734B
Maximum
Sep 2024
1.954B
Average
1.820B
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.45B |
| Biogen Inc | 542.70M |
| Johnson & Johnson | 4.952B |
| Viking Therapeutics Inc | 22.78M |
| Moderna Inc | 1.137B |